A Phase II Trial to Assess the Activity of 17-Allylamino, 17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic (M1, M1b & M1c) Malignant Melanoma

Trial Profile

A Phase II Trial to Assess the Activity of 17-Allylamino, 17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic (M1, M1b & M1c) Malignant Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2013

At a glance

  • Drugs Tanespimycin (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 26 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top